Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 831.43 Thousand EUR | -98.07% |
| 2022 | 7.97 Million EUR | 181.93% |
| 2021 | 6.92 Million EUR | -36.35% |
| 2020 | -7.14 Million EUR | -17.31% |
| 2019 | -6.08 Million EUR | -108.78% |
| 2018 | -2.91 Million EUR | -357.4% |
| 2017 | -637.62 Thousand EUR | 79.69% |
| 2016 | -3.13 Million EUR | 52.0% |
| 2015 | -6.53 Million EUR | -17.94% |
| 2014 | -6.34 Million EUR | -1132.51% |
| 2013 | -449.88 Thousand EUR | -32.88% |
| 2012 | -338.54 Thousand EUR | 75.74% |
| 2011 | -1.39 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.37 Million EUR | -100.0% |
| 2024 Q2 | -2.68 Million EUR | 0.0% |
| 2023 FY | - EUR | -98.07% |
| 2023 Q3 | - EUR | 100.0% |
| 2023 Q4 | 1.31 Million EUR | 0.0% |
| 2023 Q2 | -563 Thousand EUR | 0.0% |
| 2023 Q1 | - EUR | 100.0% |
| 2022 Q2 | -4.52 Million EUR | -110.77% |
| 2022 Q1 | -2.14 Million EUR | 52.45% |
| 2022 FY | - EUR | 181.93% |
| 2022 Q4 | -3.47 Million EUR | -95.99% |
| 2022 Q3 | -1.77 Million EUR | 60.8% |
| 2021 Q4 | -4.51 Million EUR | -100.01% |
| 2021 Q1 | -3.7 Million EUR | -0.45% |
| 2021 FY | - EUR | -36.35% |
| 2021 Q3 | -2.25 Million EUR | 56.89% |
| 2021 Q2 | -5.23 Million EUR | -41.24% |
| 2020 Q2 | -3.54 Million EUR | -100.01% |
| 2020 Q4 | -3.68 Million EUR | -105.14% |
| 2020 FY | - EUR | -17.31% |
| 2020 Q1 | -1.77 Million EUR | 52.61% |
| 2020 Q3 | -1.79 Million EUR | 49.36% |
| 2019 Q2 | -2.36 Million EUR | -100.0% |
| 2019 Q3 | -1.87 Million EUR | 20.79% |
| 2019 FY | - EUR | -108.78% |
| 2019 Q1 | -1.18 Million EUR | -34.69% |
| 2019 Q4 | -3.74 Million EUR | -100.0% |
| 2018 Q3 | -877.51 Thousand EUR | 8.26% |
| 2018 Q4 | -877.51 Thousand EUR | 0.0% |
| 2018 FY | - EUR | -357.4% |
| 2018 Q2 | -956.5 Thousand EUR | 0.0% |
| 2018 Q1 | -956.5 Thousand EUR | -43.21% |
| 2017 FY | - EUR | 79.69% |
| 2017 Q4 | -667.92 Thousand EUR | 0.0% |
| 2017 Q3 | -667.92 Thousand EUR | 3.98% |
| 2017 Q2 | -695.61 Thousand EUR | 0.0% |
| 2017 Q1 | -695.61 Thousand EUR | 41.94% |
| 2016 Q2 | -973.41 Thousand EUR | -0.0% |
| 2016 FY | - EUR | 52.0% |
| 2016 Q4 | -1.19 Million EUR | -88.61% |
| 2016 Q3 | -635.21 Thousand EUR | 34.74% |
| 2016 Q1 | -973.41 Thousand EUR | 39.22% |
| 2015 Q3 | -803.89 Thousand EUR | 68.7% |
| 2015 FY | - EUR | -17.94% |
| 2015 Q1 | -2.56 Million EUR | 1.29% |
| 2015 Q2 | -2.56 Million EUR | -0.0% |
| 2015 Q4 | -1.6 Million EUR | -99.21% |
| 2014 Q1 | -372.3 Thousand EUR | -214.88% |
| 2014 Q3 | -2.6 Million EUR | -219.69% |
| 2014 Q2 | -813.98 Thousand EUR | -118.64% |
| 2014 Q4 | -2.6 Million EUR | 0.0% |
| 2014 FY | - EUR | -1132.51% |
| 2013 FY | - EUR | -32.88% |
| 2013 Q4 | -118.23 Thousand EUR | -22.62% |
| 2013 Q1 | -108.3 Thousand EUR | 0.0% |
| 2013 Q3 | -96.42 Thousand EUR | 59.15% |
| 2013 Q2 | -236.01 Thousand EUR | -117.93% |
| 2012 FY | - EUR | 75.74% |
| 2011 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biohit Oyj | 2.68 Million EUR | 69.08% |
| Nanoform Finland Oyj | -17.65 Million EUR | 104.71% |